KINETA INC (KA)

What's going on in today's pre-market session

Friday's pre-market session: top gainers and losers

Stay updated with the stocks that are on the move in today's after-hours session.

Tuesday's after hours session: top gainers and losers

Tuesday's session: top gainers and losers

Wondering how the US markets performed one hour before the close of the markets on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis.

Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes.

Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements.

Top movers in Tuesday's session

Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes.

Get insights into the top gainers and losers of Monday's after-hours session.

Get insights into the top gainers and losers of Monday's after-hours session.

Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical Trial

Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts

KA Stock Earnings: Kineta Beats EPS for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Kineta (NASDAQ:KA) just reported results for the fourth quarter of 2023.Kineta ...

KA Stock Earnings: Kineta Beats EPS for Q4 2023

KA stock results show that Kineta beat analyst estimates for earnings per share the fourth quarter of 2023.

Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update

Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts in the VISTA-101 trial No...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

Pre-market stock movers are worth checking on Friday as investors prepare for the last day of trading this week with all of the latest news!

Kineta stock falls ~25.7% after co cuts workforce by 64%, including CEO (NASDAQ:KA)

Kineta is slashing its workforce by 64% and terminating enrollment in a clinical trial, causing shares to plummet 25.66%.

Kineta to Present New Preclinical Data on its Anti-VISTA Antibody KVA12123 in Acute Myeloid Leukemia at the AACR Blood Cancer Discovery Symposium

SEATTLE, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel...

Kineta to Present at Upcoming Investor Conferences

SEATTLE, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel...

Kineta to Participate in H.C. Wainwright Virtual @Home Fireside Chat Series

SEATTLE, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel...

Kineta Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tumors

Cleared First Four Monotherapy Doses and Initial Combination Cohort with No Dose Limiting Toxicities at any Dose Level KVA12123 Monotherapy...

Kineta to Participate in the 13th Annual LifeSci Partners Corporate Access Event

SEATTLE, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel...

Life Science Investor Forum: Presentations Now Available for Online Viewing

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com

Kineta Publishes Preclinical Data Demonstrating the Potential of Anti-VISTA Antibody KVA12123 as an Immunomodulatory Therapy for Cancer

VISTA Blocking KVA12123 Monoclonal Antibody (mAb) Engineered to Provide Strong Single Agent Anti-Tumor Activity While Minimizing Cytokine Related Adverse...

Life Science Investor Forum Agenda Announced for December 14th, 2023

Kineta to Present at the Life Sciences Investor Forum December 14th

Company invites individual and institutional investors, as well as advisors and analysts, to attend in person or online at VirtualInvestorConferences.com

Kineta to Host KOL Event to Review New Data from VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tumors on December 5, 2023

SEATTLE, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel...

Kineta to Present at the 5th Annual Macrophage-Directed Therapies Summit

SEATTLE, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel...

Kineta files to sell 890K shares of common stock for holders (NASDAQ:KA)

Read about Kineta's filing of a resale prospectus for up to 890,208 shares of common stock. This article is not an offer to sell.